Resources

Explore our online resource catalog to discover publications, presentations, tools, and related resources for global health practitioners, decision-makers, advocates, and more.

All resources

Read our latest

2395 Result s
2395 Result s
    Date
    From
    To
  1. This is a simple, Excel-based tool for assessing and comparing costs of human papillomavirus (HPV) vaccination programs with each HPV vaccine product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different HPV vaccines, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost plus cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting an HPV vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. The tool is available to download in multiple languages. If you have additional questions or need support, contact PATH's Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.
    Published: November 2026
    Resource Page
    Part of a Series, Training Material
  2. This is a simple, Excel-based tool for assessing and comparing costs of human papillomavirus (HPV) vaccination programs with each HPV vaccine product available in the global market. It aims to help national-level policymakers specifically in middle-income countries compare products and estimate vaccination program costs for different HPV vaccines, exploring up to four different vaccine options at a time. The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery).It is important to note that cost is only one consideration when selecting an HPV vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages. Please be sure to check out this six-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.
    Published: November 2026
    Resource Page
    Part of a Series, Training Material
  3. To lower the risk of cancers associated with human papillomavirus (HPV), Burkina Faso introduced HPV vaccination into its routine immunization program. The campaign provided nine-year-old girls with vaccine access, in accordance with the current immunization schedule. The initiative was launched off in April 2022 following a successful demonstration phase in 2017. Learn more about the key takeaways from multistakeholder consultation workshops.
    Published: October 2026
    Resource Page
    Part of a Series, Fact Sheet
  4. Ethiopia introduced human papillomavirus (HPV) vaccination in December 2018 to reduce the risk of HPV-associated cancers. Initially administered as a two-dose schedule to 14-year-old girls, the country adopted a single-dose strategy in 2023. Coverage estimates¹ for 2023 ranged from 56 to 86 percent, highlighting gaps in reaching eligible girls, particularly those out of school or in hard-to-reach areas. Learn more about the key takeaways from multistakeholder consultation workshops.
    Published: October 2026
    Resource Page
    Part of a Series, Fact Sheet
  5. Kenya introduced human papillomavirus (HPV) vaccination into its routine immunization schedule in October 2019 to protect against HPV-associated cancers. The program targets ten-year-old girls through a mixed-delivery model combining primarily facility-based services with school-based outreach. HPV1 coverage reached 33 percent in 2020. Learn more about the key takeaways from multistakeholder consultation workshops.
    Published: October 2026
    Resource Page
    Part of a Series, Fact Sheet